Circulating Tumor Cell Market Outlook - 2030

Circulating tumor cell testing enables the detection and quantification of tumor cells in the blood of cancer patients. Different biological phenotypes of CTCs exist: epithelial, mesenchymal, stem cell-like or mixed. They are present in blood in very small quantities, vastly outnumbered by other cells, especially white blood cells. As a result, their detection needs a phase of isolation-enrichment and a second phase of detection. All the recent CTC identification devices combine these two steps (isolation-enrichment and detection) such as ISET, CellSearch System, CTC-chip or EPISPOT. Sometimes, different methods are used in the same device for one step: for instance, the RosetteSep device includes 2 methods of enrichment/isolation: by density and by immunologic separation which is a negative selection. A number of potential applications of circulating tumor cells in prediagnosis, pre-treatment, and intra and post-treatment provide lucrative growth opportunities to players involved in the development of circulating tumor cell (CTC) enrichment and isolation products.

Circulating Tumor Cell Market scope and structural analysis:

Covid-19 Scenario analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the circulating tumour cell market

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact analysis:

Increased demand for efficient diagnostic and screening tests and technological advancements in cancer detection is expected to propel the growth of market for CTCs. Several tumor markers that have been introduced in recent years can be used with companion diagnostics to monitor or diagnose a variety of cancers. High adoption of companion diagnostics in monitoring tumor eradication characteristics of cytotoxic drugs is among the few factors propelling the demand in the market for CTCs. Key stakeholders are constantly engaged in endeavours aimed at developing circulating tumor cells based tests, which can prove helpful in the cancer diagnosis. The circulating tumor cell testing is also a useful tool for the development of preventive medicine for cancer. Circulating tumor cell testing can help understand and asses the mechanism of drug during in-vitro experiment in preclinical studies.

Drivers:

Increase in preference for minimum invasive procedure:

Growing demand for minimally invasive diagnostic procedures is anticipated to propel investments by key stakeholders in this area. Circulating tumor cell based liquid biopsy tests lead to limited trauma and enable rapid recovery owing to their non-invasive nature. Moreover, it enables minimal invasive screening of tumors before opting for complex surgical procedures, such as radiotherapy, chemotherapy, and surgical removal of tumors, thus positively impacting the adoption.

Increase in prevalence rate of cancer:

The growing prevalence of cancer is one of the major reasons behind the growth of circulating tumor cell testing market. According to NIH, National Cancer Institute, cancer is one of the major reasons of death globally. According to an estimation from the National Cancer Institute, in 2018 colorectal cancer is projected to contribute around 8.1% of all new cancer cases with estimated deaths around 50,630, which is 8.3% of all cancer deaths caused in the U.S.As reported by the Cancer Research UK, there were 41,804 new cases of colorectal cancer in 2015 and 16,384 deaths due to colon cancer in the U.K.

Increase in genetic disorder, alcohol consumption, smoking and lifestyle changes are the major factor behind the rise in cancer cases and also contributing factor for the growth of the circulating tumor cell market.

Key Market players:

• In March 2018, Biocept Inc received a patent for its Target Selector assays for molecular analysis to improve the patient diagnosis with cancer in China.
• In May 2021, Natera, a company involved in non-invasive genetic testing and the analysis of circulating cell-free DNA, to present successful results of Signatera, to monitor colorectal cancer and identify disease recurrence.

Key segments covered:

Key benefits of the report:

• This study presents the analytical depiction of the global circulating tumor cell industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global circulating tumor cell market share.
• The current market is quantitatively analyzed from 2021 to 2030 to highlight the global circulating tumor cell market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed global circulating tumor cell market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Circulating tumor cell Market research report:

• What are the leading market players active in the circulating tumor cell market?
• What the current trends will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities in the market?
• What are the projections for the future that would help in taking further strategic steps?